Cerulean Pharma (United States)

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart et al. · Investigational New Drugs · 2013 · 219 citations · Full text

Oncology, Polymer-drug Conjugate, Medicine +7

Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101

Sönke Svenson, Marc Wolfgang, Jungyeon Hwang et al. · Journal of Controlled Release · 2011 · 148 citations · Full text

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Scott Eliasof, Douglas Lazarus, Christian Peters et al. · Proceedings of the National Academy of Sciences · 2013 · 141 citations · Full text

Nanoparticles, Nanomedicine, Engineering +15

CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development

Cissy Young, Thomas Schluep, Jungyeon Hwang et al. · Current Bioactive Compounds · 2011 · 105 citations · Full text

Nanotherapeutics, Engineering, Unique Design Features +22

CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α

Xi Tian, Minh Nguyen, Henry P. Foote et al. · Cancer Research · 2016 · 79 citations · Full text

Nanotherapeutics, Tumor Biology, Novel Agents +16